Thursday, November 12, 2009

Osteoporosis Home>
News>
Osteoporosis med Reclast approved for men in Europe

Font size
- A
- A
- A
Email This

Bookmark

Save

Osteoporosis med Reclast approved for men in Europe

(PipelineReview.com) UPDATED 2008-09-30

According to a press release from drugmaker Novartis, the European Union has approved the one-a-year osteoporosis drug Reclast for use in men who are at high risk for fracture. Reclast, which is sold as Aclasta in Europe, also received a new label that includes information about the drug's ability to reduce new fractures in both men and postmenopausal women who have osteoporosis and have recently suffered a hip fracture. Read full story >

See all Osteoporosis News

Related: Reclast

Font size
- A
- A
- A
Email This
Bookmark

Was this helpful? Yes
Save

Note: All clinical content on this site is physician-reviewed, except material generated by our community members.

Featuring Content From:

By using this service, you accept our Terms of Use. Please read them. The consumer health information on OsteoporosisConnection.com is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2005-2009. The HealthCentral Network, Inc. All rights reserved.

We comply with the HONcode standard for trustworthy health information: verify here.